Search the Newsreel

AZZ Inc. Announces August Investor Conference Schedule

FORT WORTH, Texas, Aug. 5, 2026 /PRNewswire/ -- AZZ Inc. (NYSE: AZZ), the leading independent provider of hot-dip galvanizing and coil coating solutions in North America, today announced its participation in the following investor conferences during the month of August:AZZ Inc is the leading …

AZZ webcast from Chicago will be available Aug. 26

AZZ Inc. (NYSE: AZZ) announced its participation in the Three Part Advisors 17th Annual Midwest IDEAS Conference in Chicago on August 26-27, 2026. David Nark, Chief Marketing, Communications and Investor Relations Officer, will present on August 26 at 7:55 a.m. ET and host one-on-one …

Jazz Pharmaceuticals plc Stock 12‑Month Price Target Raised to $285, Implies 13% Upside

Jazz Pharmaceuticals plc's average 12-month price target has been increased from $270.63 to $285 by 19 analysts, suggesting a 13% potential upside from its August 3rd closing price. The consensus rating for JAZZ stock remains a "Buy" among 22 analysts, with 19 recommending Buy, …

Jazz Pharmaceuticals (JAZZ) Stock Climbs As Raised Guidance Backs Oncology Push

Jazz Pharmaceuticals (JAZZ) saw its stock climb after reporting record Q2 revenue and raised full-year guidance, driven by strong performance in its neurology segment and progress in oncology. The company's Q2 revenue hit US$1.21 billion with non-GAAP EPS of US$5.71, leading to an increased …

AZZ Appoints Rhonda Davenport as Chief HR Officer

AZZ Inc. has appointed Rhonda Davenport as Chief Human Resources Officer, tasking her with overseeing various HR initiatives including talent acquisition, leadership development, and employee engagement. Davenport brings over two decades of HR leadership experience and her compensation package is performance-based, aligning with the …

Jazz Pharmaceuticals stock hits all-time high at 261.46 USD By Investing.com

Jazz Pharmaceuticals (JAZZ) stock has reached an all-time high of $261.46, marking a 130.32% increase over the past year. Despite trading near its 52-week high, InvestingPro analysis suggests the stock is undervalued. The company also reported strong second-quarter revenues of $1.21 billion, exceeding estimates, …

California State Teachers Retirement System Grows Position in Jazz Pharmaceuticals PLC $JAZZ

The California State Teachers Retirement System increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 22% in the first quarter of 2026, now holding 63,657 shares valued at $12 million. Other institutional investors also significantly grew their positions. Analysts maintain a generally bullish outlook …

Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

RBC Capital Adjusts Price Target on Jazz Pharmaceuticals to $273 From $258, Maintains Outperform Rating

RBC Capital has raised its price target for Jazz Pharmaceuticals (JAZZ) from $258 to $273, while reiterating an Outperform rating on the stock. This adjustment comes amidst other analyst updates for the biopharmaceutical company, including price target increases from Deutsche Bank and Morgan Stanley. …

What Jazz Pharmaceuticals’ Q2 Earnings Call Revealed About the Zanidatamab Bet

Jazz Pharmaceuticals reported a record Q2 revenue of $1.21 billion, a 16% year-over-year increase, prompting the company to raise its full-year revenue guidance. The strong performance was driven by significant growth in oncology sales and better-than-expected Xywav sales despite generic competition, attributed to strong …

Stifel raises Jazz Pharmaceuticals stock price target on revenue beat

JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View

Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Earnings Results, Misses Expectations By $0.47 EPS

Jazz Pharmaceuticals plc Q2 2026: Revenue $1156.1M, EPS $2.78— 10-Q Summary

Jazz Pharmaceuticals plc reported strong Q2 2026 results with revenue of $1156.1M and diluted EPS of $2.78, marking a significant improvement from the prior year's loss. Growth was fueled by key product performance, including Xywav and Epidiolex, and successful oncology launches. The company also …

Jazz Pharmaceuticals (JAZZ) swings to H1 2026 profit and trims $1B in debt

Jazz Pharmaceuticals reported a significant financial turnaround in the first half of 2026, swinging to a net income of $485.9 million compared to a net loss of $811.0 million in the prior-year period. Revenues also increased to $2,277.2 million. The company successfully reduced its …

Jazz Pharmaceuticals plc (JAZZ) Earnings Preview

This article previews Jazz Pharmaceuticals plc's upcoming earnings report, highlighting the company's position as a global biopharmaceutical player in neuroscience and oncology. It emphasizes key challenges and opportunities, including the transition of its oxybate franchise, pipeline execution, and the need to sustain profitability amidst …

Compared to Estimates, Jazz (JAZZ) Q2 Earnings: A Look at Key Metrics

Jazz Pharmaceuticals (JAZZ) Earnings Date and Reports 2026 $JAZZ

Jazz Pharmaceuticals (JAZZ) Q2 Earnings Lag Estimates

JAZZ Looks 68.1% Overvalued on GF Value™

Jazz Pharmaceuticals (NASDAQ: JAZZ) is scheduled to report its second-quarter earnings on August 3rd, amidst an elevated Price-to-Sales ratio of 3.55, suggesting it is 68.1% overvalued according to its GF Value™. Despite a strong GF Score of 73 highlighting profitability and growth, concerns are …

Precision Trading with Jazz Pharmaceuticals Plc (JAZZ) Risk Zones

This article provides a precision trading analysis for Jazz Pharmaceuticals Plc (JAZZ), highlighting strong sentiment across all horizons and tested resistance levels. It outlines specific institutional trading strategies, including long, breakout, and short setups with defined entry, target, and stop-loss zones. The analysis is …

Jazz Pharmaceuticals PLC (JAZZ) Financial Health: Profitability & Balance Sheet Analysis

Jazz Pharmaceuticals PLC (JAZZ) has a stable financial score of 8.58, ranking 40th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 19.05% year-over-year revenue increase to $1.07 billion and a remarkable 416.72% increase in net profit. …

AZZ Inc. Announces Acquisition of Seattle Galvanizing Company, Inc.

AZZ Inc. (NYSE: AZZ) has acquired 100% of Seattle Galvanizing Company Inc., a multi-site provider of hot-dip and spin galvanizing solutions based in Arlington, Washington. This acquisition expands AZZ's galvanizing network to 43 sites in North America, establishing its first direct presence in the …

Is AZZ (AZZ) Undervalued As Investors Weigh Its Recent Pullback And Fair Value Debate?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AZZ (AZZ) has moved onto Zacks.com's most searched stocks list, reflecting fresh attention after recent changes in earnings estimates and stock performance. Investors …

Should Anticipated Earnings Beat and Employer Award Recognition Require Action From Jazz Pharmaceuticals (JAZZ) Investors?

Jazz Pharmaceuticals (JAZZ) is projected to report a significant year-over-year earnings increase for Q2 2026 and recently received a Gold Stevie Award for Employer of the Year, indicating strong operational performance and a positive workplace culture. While these factors boost near-term confidence, investors should …

AZZ Inc. (AZZ) is Attracting Investor Attention: Here is What You Should Know

AZZ (AZZ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this electrical equipment maker …

AZZ Inc (AZZ) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for AZZ Inc (AZZ), highlighting its current earnings forecast score and ranking within the Metals & Mining industry. It details analyst ratings, price targets, and expected EPS and revenue for upcoming periods. Most analysts recommend a "Buy" trend …

Jazz Pharmaceuticals (JAZZ) Projected to Announce Earnings on Monday

Jazz Pharmaceuticals (JAZZ) is expected to report its Q2 2026 earnings after market close on Monday, August 3rd, with analysts projecting $6.18 EPS and $1.114 billion in revenue. The company's stock has risen, trading near its 12-month high with a "Moderate Buy" consensus from …

Jazz Pharmaceuticals PLC (JAZZ) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Jazz Pharmaceuticals PLC (JAZZ) stock performance, showing a closing price of $255.440 and a market cap of $15.69 billion. It notes that the company has not distributed any dividends over the past five years. The page also includes current …

Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth

AZZ Inc. Revenue Breakdown – NYSE:AZZ

TradingKey

This article provides a detailed cash flow statement for Jazz Pharmaceuticals PLC (JAZZ) across numerous quarters and fiscal years. It includes operating, investing, and financing cash flows, along with related financial metrics like capital expenditures and free cash flow. The data is presented with …

Jazz Pharmaceuticals (JAZZ) Stock Still Looks Cheap As Shares Jumped 115%

Jazz Pharmaceuticals (JAZZ) stock has seen a significant 115% jump over the past year, yet Simply Wall St's valuation checks present a mixed picture, suggesting it's not a clear bargain or clearly overvalued. While the company screens as undervalued on 4 of 6 measures …

Jazz Pharmaceuticals plc Revenue Breakdown – NASDAQ:JAZZ

Jazz Pharmaceuticals plc generated $4.27 billion USD last year, primarily from its Pharmaceutical Products segment. This represents an increase from $4.07 billion USD in the previous year. The United States was the largest contributor to revenue, accounting for $3.83 billion USD.

AZZ|AZZ Inc|Price:149.900|Chg%:-2.640

AZZ Inc. (AZZ) is trading at $149.90, down 1.73%, with a market cap of $4.50 billion. TradingKey's stock score indicates stable fundamentals, high growth potential, and a fair valuation within the Metals & Mining industry. Institutional ownership is high, and analysts largely rate it …

JAZZ|Jazz Pharmaceuticals PLC|Price:253.870|Chg%:-1.000

Jazz Pharmaceuticals PLC is currently trading at $253.870, experiencing a slight decrease of 0.39%. Despite a recent turnaround to a loss and institutional selling, the company's fundamentals are considered healthy with high growth potential, and it is currently rated as a "Buy" by analysts …